Drugmaker Insmed Inc. said it had bought the rights to an experimental early-stage respiratory drug from Britain’s AstraZeneca Plc in a deal worth $150 million.

The U.S. Food and Drug Administration approved Amgen’s biosimilar version of AbbVie’s top-selling arthritis drug Humira.

In yet another buy in its string of acquisitions, Dublin-based Allergan announced it was acquiring San Francisco-based Tobira Therapeutics.

Eating a handful of nuts five times per week may reduce inflammation, a condition that contributes to heart disease, diabetes and many other chronic illnesses, say the authors of a recent U.S. study.

Merck & Co’s immunotherapy Keytruda led to a high response rate for patients with the blood cancer multiple myeloma when added to standard therapy in a small, early stage trial, according to data presented on Monday. The Phase I study tested Keytruda in combination with Celgene’s Revlimid and the corticosteroid dexamethasone in patients whose disease […]

THOUSAND OAKS, Calif. and KENILWORTH, N.J., Dec. 4, 2015 /PRNewswire/ — Amgen (NASDAQ: AMGN) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced a cancer immunotherapy collaboration to support a Phase 1b/3 study investigating BLINCYTO® (blinatumomab) in combination with KEYTRUDA® (pembrolizumab) in patients with diffuse large B-cell lymphoma (DLBCL), which […]

AstraZeneca’s experimental lupus drug anifrolumab significantly cut disease activity in a mid-stage clinical trial, boosting hopes for a medicine the company believes could become a $1 billion-a-year seller. The drugmaker said on Tuesday that the new treatment was more effective than another drug, sifalimumab, that it had also been testing in lupus. It has therefore […]

Phase I first-in-human study to evaluate GSK’s OX40 agonist GSK3174998 as monotherapy and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab)     LONDON & KENILWORTH, N.J.–(BUSINESS WIRE)–GSK and Merck, known as MSD outside the US and Canada, today announced the initiation of a phase I clinical trial designed to evaluate GSK’s investigational immunotherapy GSK3174998 […]

Staff reviewers of the U.S. Food and Drug Administration have raised questions about the safety of AstraZeneca Plc’s gout treatment. Reviewers pointed to higher death rates, cardiovascular issues and kidney-related side effects in patients who took the drug, lesinurad, a preliminary review published on Wednesday showed. Industry analysts forecast annual sales of the drug to […]

Johnson & Johnson’s Stelara was significantly better than placebo at inducing clinical response and remissions in patients with moderate to severe Crohn’s disease, according to data from a late stage trial, providing ammunition for a potential expanded approval of the medicine. Stelara, a biotech medicine that blocks inflammation, is approved to treat the skin condition […]